Efficacy of an Aqueous and a Powder Formulation of Nasal Budesonide Compared in Patients with Nasal Polyps

1998 ◽  
Vol 12 (3) ◽  
pp. 183-190 ◽  
Author(s):  
Mirko Tos ◽  
Frank Svendstrup ◽  
Helge Arndal ◽  
Steffen Ørntoft ◽  
John Jakobsen ◽  
...  
Keyword(s):  
Nasal Polyps ◽  
Treated Group ◽  
Nasal Symptom ◽  
Primary Efficacy Variable ◽  
Treatment Alternative ◽  
Polyp Size ◽  
Sense Of Smell ◽  
Nasal Symptoms ◽  
Symptom Scores ◽  
Overall Evaluation

Nasal polyps are commonly treated surgically. Intranasal administration of topical corticosteroids has gained increased acceptance as a treatment alternative. The aim of our study was to compare the efficacy of treatment of two formulations of budesonide with placebo on nasal polyps. At four Danish clinics 138 patients suffering from moderate or severe nasal polyps were randomized to a twice daily treatment with Rhinocort® Aqua 128 μg, Rhinocort Turbuhaler® 140 μg or placebo (Astra Draco, Sweden) for 6 weeks. Polyp size (primary efficacy variable), nasal symptoms, sense of smell, and patients’ overall evaluation of treatment of efficacy were assessed by scores. Polyp size was reduced significantly in both budesonide treated groups compared with placebo, but there was no statistical difference between the two actively treated groups. Patients’ nasal symptom scores was significantly more reduced in the Aqua compared to the Turbuhaler treated group, and both reduced symptom scores were significantly better compared to placebo. Sense of smell was significantly improved in the actively treated groups compared to placebo. The proportion of patients rating substantial or total control over symptoms after 6 weeks treatment was 60.9% and 48.2% in the Aqua and Turbuhaler-treated groups, respectively, which was significantly better compared with 29.8% in the placebo-treated group. Rhinocort Aqua and Rhinocort Turbuhaler were equally well tolerated.

S290 – Sinonasal Pathology and Severity of Bronchiectasis

2008 ◽  
Vol 139 (2_suppl) ◽  
pp. P171-P172
Author(s):  
Jose Maria Guilemany ◽  
Isam Alobid ◽  
Centellas Silvia ◽  
Manuel S Bernal-Sprekelsen ◽  
Joaquim Mullol I Miret
Keyword(s):  
Maxillary Sinus ◽  
Chronic Rhinosinusitis ◽  
Nasal Polyps ◽  
Nasal Polyposis ◽  
Nasal Congestion ◽  
Ethmoid Sinus ◽  
Polyp Size ◽  
Moderate Size ◽  
Nasal Symptoms ◽  
Ostiomeatal Complex

Objectives 1) To investigate the prevalence of nasal symptoms, nasal polyposis, and sinusal opacification in patients with bronchiectasis. 2) To investigate the association between the degree of sinusal opacification and the bronchiectasis extension. Methods 88 consecutive patients with stable non-cystic bronchiectasis were prospectively evaluated for nasal symptoms (RASP, 0–3), polyp size (nasal endoscopy, 0–3), sinusal occupation (CT, 0–24), and chest HRCT (0–18). Results Following EP3OS criteria, 77% of patients presented had chronic rhinosinusitis (CRS). Nasal congestion (incidence: 90%; score: 1.6±0.1) Anterior (99%; 1.9±0.1) and posterior (91%; 1.8±0.1) rhinorrhea, were reported by patients as the major complaints. Nasal polyps (NP) of a mild-moderate size (1.6±0.3) were found in 25% of patients. Sinonasal CT was abnormal in patients with CRS, with a CT score of 8.4±0.4, with predominance in maxillary sinus (2.1±0.1), anterior ethmoid sinus (1.9±0.1), and ostiomeatal complex (2.2±0.2). Patients with CRS had significantly worse scores on chest HRCT (CRS: 3.7±0.7; no CRS: 7.2±0.5). Conclusions More than 75% of patients affected with BQs fulfil EP3OS criteria of CRS and 25% of patients presented NP. Patients with CRS presented more affectation on chest HRCT scan. We conclude that patients with bronchiectasis should be evaluated to assess the presence of chronic rhinosinusitis and nasal polyposis.

scholarly journals Efficacy of Mometasone Furoate and Fluticasone Furoate on Persistent Allergic Rhinoconjunctivitis

2013 ◽  
Vol 4 (3) ◽  
pp. ar.2013.4.0065 ◽  
Author(s):  
W. Hamizan Aneeza ◽  
Salina Husain ◽  
Roslenda Abdul Rahman ◽  
Dexter Van Dort ◽  
Asma Abdullah ◽  
...  
Keyword(s):  
Symptom Score ◽  
Nasal Symptom ◽  
Allergic Rhinoconjunctivitis ◽  
Mometasone Furoate ◽  
Fluticasone Furoate ◽  
Ocular Symptoms ◽  
Nasal Symptoms ◽  
Total Nasal Symptom Score ◽  
Significant Difference ◽  
Symptom Scores

Allergic rhinoconjunctivitis denotes both nasal and ocular manifestation of allergy, which may be solely treated with intranasal steroid. This study compares the efficacy of mometasone furoate nasal spray (NS) and fluticasone furoate NS in treatment of allergic rhinoconjunctivitis. The secondary objective is to study the severity of baseline ocular symptoms in allergic rhinoconjunctivitis. Seventy-eight patients with allergic rhinoconjunctivitis were assessed subjectively and objectively using twice-daily symptom scores for nasal (reflective total nasal symptom score [rTNSS] and instantaneous TNSS [iTNSS]) and ocular (reflective total ocular symptom score [rTOSS] and instantaneous TOSS [iTOSS]) symptoms, rhinoconjunctivitis quality-of-life questionnaires (RQOLQs), and acoustic rhinometry. All measurements were taken at baseline and at 4 and 8 weeks of treatment. Sixty-three patients who were randomized into the mometasone furoate group (n = 36) and the fluticasone furoate group (n = 27) completed the study. Seventy-six percent of patients had mild ocular symptoms, 20.5% had moderate symptoms, and only 2.6% had severe symptoms at baseline based on the iTOSS; 65.1% had mild nasal symptoms and 3% had severe nasal symptoms. There was significant reduction in the symptom scores after 1 week (p < 0.05). Both groups had significant improvement in RQOLQ scores after 1 month, which further improved at 2 months (p < 0.05). The nasal dimensions also improved in both groups (p < 0.05) but there was no statistically significant difference between groups. Both mometasone furoate and fluticasone furoate are effective as single-modality treatment of allergic rhinoconjunctivitis. The majority of patients manifest mild ocular symptoms that may be solely treated with intranasal steroids.

Sinonasal effects of external dacryocystorhinostomy

2021 ◽  
pp. 1-4
Author(s):  
H Eyigor ◽  
E A Cetinkaya ◽  
D T Coban ◽  
G Ozturk ◽  
Ö Erdem
Keyword(s):  
Mucociliary Clearance ◽  
Nasal Symptom ◽  
Ciliary Activity ◽  
Test Results ◽  
Saccharine Test ◽  
Significant Difference ◽  
Symptom Scores ◽  
Endoscopic Score ◽  
External Dacryocystorhinostomy

Abstract Objective External dacryocystorhinostomy is thought to cause mucociliary dysfunction by damaging the mucosa, in turn affecting ciliary activity and mucus quality. This study investigated the effect of external dacryocystorhinostomy on sinonasal function. Methods Patients scheduled for unilateral external dacryocystorhinostomy who underwent endoscopic nasal examination and paranasal sinus computed tomography were included in this study. A saccharine test was performed on the planned surgical side and the mucociliary clearance time was determined. The sinonasal quality of life was measured in all patients, pre-operatively and at six months post-operatively, using the Sino-Nasal Outcome Test-22. The Lund–Kennedy endoscopic score was also determined in all patients, both pre- and post-operatively. Results The study comprised 28 patients (22 females and 6 males). A statistically significant difference was found between the pre- and post-operative saccharine test results (p = 0.006), but not between the pre- and post-operative Sino-Nasal Outcome Test-22 scores (p > 0.05). Conclusion This study is one of only a few to investigate the effect of external dacryocystorhinostomy on sinonasal function. The results showed that external dacryocystorhinostomy impairs mucociliary clearance. The surgical procedure is well tolerated and does not significantly change nasal symptom scores.

S103 – Mometasone Is Effective With or Without Oral Antihistamines

2008 ◽  
Vol 139 (2_suppl) ◽  
pp. P112-P112
Author(s):  
Joao Antonio Marta Pimentel
Keyword(s):  
Nasal Discharge ◽  
Daily Routine ◽  
Efficacy And Safety ◽  
Concomitant Therapy ◽  
Open Label ◽  
Daily Routines ◽  
Oral Antihistamine ◽  
Intranasal Corticosteroids ◽  
Nasal Symptoms ◽  
Symptom Scores

Objectives Clinical trials have demonstrated the efficacy of monotherapy with intranasal corticosteroids (INSs) for symptoms of allergic rhinitis (AR). ARIA guidelines suggest adding oral antihistamines to INS monotherapy when severe symptoms do not improve. An open-label multicenter study assessed efficacy and safety of mometasone furoate nasal spray (MFNS) alone or combined with an oral antihistamine in subjects with AR. Methods Subjects received MFNS 200 mcg QD for 56 days, with an oral antihistamine added at Day 28 or later if baseline symptoms (sneezing, nasal discharge/obstruction, tiredness, irritability) had not improved. Subjects rated individual symptom scores, daily routine and sleep limitations, and product attributes on Days 1, 28, and 56 on a scale of 0 to 10, and completed a compliance questionnaire on Day 56. Results Mean scores for AR symptoms and limitations on sleep and daily routines significantly improved from baseline to Day 28 and from Day 28 to 56 (P less than 0.001 for all). At Days 28 and 56, 47/60 and 45/56 subjects, respectively, were receiving MFNS monotherapy, and 13 required a concomitant oral antihistamine at Day 28 or later. By Day 56, symptom severity improved in 92% of subjects receiving concomitant therapy. At study end, 88% of subjects reported compliance with QD MFNS. Average product attribute scores ranged from 7.2 to 8.4. No severe adverse events were reported. Conclusions MFNS 200 mcg QD, alone or combined with an oral antihistamine, was safe and effective against AR nasal symptoms and limitations of sleep and daily activities.

Nasal vestibulitis: An MNCCTN natural history trial—Nasal vestibulitis symptoms associated with paclitaxel, docetaxel, and other chemotherapy agents.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e24086-e24086
Author(s):  
Elizabeth Jane Cathcart-Rake ◽  
David Zahrieh ◽  
Deanne s. Smith ◽  
Susan Young ◽  
Eric G. Wolfe ◽  
...  
Keyword(s):  
Natural History ◽  
Side Effect ◽  
Nasal Symptom ◽  
Smoking History ◽  
Common Side Effect ◽  
Point Scale ◽  
Nasal Symptoms ◽  
History Of ◽  
New Treatment ◽  
Taxane Chemotherapy

e24086 Background: Nasal vestibulitis has been infrequently described as a side effect of cancer-directed therapy; however, a preliminary study reported that 71% of patients undergoing taxane chemotherapy experienced nasal vestibulitis symptoms. This natural history trial describes the incidence, characteristics, and severity of nasal vestibulitis symptoms among patients undergoing paclitaxel, docetaxel, and non-taxane chemotherapy. Methods: Eligible participants who reported baseline (prior to starting chemotherapy) nasal symptoms ≤ 2 on a 10-point scale were enrolled in this trial upon initiation of a new treatment regimen, involving paclitaxel or docetaxel, or non-taxane chemotherapy. Participants completed nasal symptom logs each time they received a dose of therapy until either the regimen was stopped or four months had passed. The proportion of patients reporting new nasal symptoms was estimated within each cohort with the 95% exact confidence interval (CI). A cumulative incidence model was utilized to quantify the incidence of treatment-emergent nasal symptoms within each cohort, while controlling for age, sex, smoking history, and history of asthma or allergies. Results: Thirty-five participants received paclitaxel, 21 received docetaxel, and 25 received other types of chemotherapy. 86.4% of participants were female, mean age was 60.2 ± 11.2 years; 93.8% of participants completed 2 or more surveys. A higher percentage of participants in the paclitaxel cohort experienced new nasal vestibulitis symptoms than participants in the other two cohorts. The percentage (95% CI) of participants with nasal symptoms, for patients receiving paclitaxel, docetaxel, and non-taxane chemotherapy were 74.3% (56.7%, 87.5%), 47.6% (25.7%, 70.2%), and 44.0% (24.4%, 65.1%), respectively. Epistaxis was reported by 60% of participants in the paclitaxel cohort. Paclitaxel-receiving participants also reported nasal dryness (48.6%), scabbing (40.0%), and pain (20.0%). Nearly half of participants reported moderate symptoms (4-7 out of a 10-point scale), with 8.6% reporting symptoms as severe (8-10 on a 10-point scale). Conclusions: Nasal vestibulitis is a common side effect of chemotherapy, especially paclitaxel chemotherapy.

scholarly journals Association of chronic rhinosinusitis with nasal polyps and asthma: Clinical and radiological features, allergy and inflammation markers

Medicina ◽  
2008 ◽  
Vol 44 (4) ◽  
pp. 257 ◽  
Author(s):  
Jūratė Staikūnienė ◽  
Saulius Vaitkus ◽  
Lidija Japertienė ◽  
Silvija Ryškienė
Keyword(s):  
Allergic Rhinitis ◽  
Pulmonary Function ◽  
Chronic Rhinosinusitis ◽  
Systemic Inflammation ◽  
Eosinophil Count ◽  
Nasal Polyps ◽  
Older Age ◽  
Bronchial Obstruction ◽  
Inflammation Markers ◽  
Nasal Symptoms

Chronic rhinosinusitis (CRS) with and without nasal polyps represent different stages of one chronic inflammatory disease of the mucosa of the nasal cavity and paranasal sinuses. Coexistence of chronic rhinosinusitis with nasal polyps and asthma and rather similar characteristics of inflammation support assumption that chronic rhinosinusitis and nasal polyps and asthma may be, at least in part, the same disease process. We therefore aimed to evaluate the differences of sinus radiologic findings, systemic inflammation and allergy markers, pulmonary function of chronic rhinosinusitis associated with nasal polyps and asthma. A total of 121 patients with chronic rhinosinusitis referred to tertiary center were evaluated; 23 healthy persons served as controls. Sinus CT scans and nasal endoscopy were performed. Allergic rhinitis was diagnosed according to history and positive skin prick tests to common inhalant allergens. Asthma was diagnosed according to GINA by history and pulmonary function tests. Aspirin intolerance was assessed by history. Total IgE, Aspergillus fumigatus-specific IgE levels, leukocyte and eosinophil count in the peripheral blood were measured. Nasal polyps were detected in 84 patients (69.4%), asthma diagnosed in 48 patients (39.6%), associated with nasal polyps (91.7%) and allergic rhinitis in 45.5% of patients. Forty-four patients with chronic rhinosinusitis and having nasal polyps and asthma were characterized by older age (P<0.01), greater duration of nasal symptoms (P<0.001), higher number previous surgeries (P<0.01), more severe sinus disease on CT scan (P<0.001), greater blood leukocyte and eosinophil count, total IgE level (P<0.01), bronchial obstruction (P<0.05), incidence of allergic rhinitis (P<0.01), and sensitivity to house dust mite D. pteronyssinus (47.7%, P<0.01) and mold allergens (29.5%, P<0.01) comparing to the patients with isolated chronic rhinosinusitis. The extent of sinus CT changes was greater in asthmatics and correlated with greater duration of asthma (P<0.0001), higher number of previous surgeries (P=0.001), leukocyte count in blood (P=0.025), and age (P=0.039). Conclusion. Our data indicate that patients with chronic rhinosinusitis compose clinically heterogeneous group and when associated with nasal polyps and asthma constitutes the most severe form of unified respiratory tract disease, which is characterized by older age of the patients, greater duration of nasal symptoms, extent of sinus radiological changes, more prominent systemic inflammation markers, greater bronchial obstruction, incidence of perennial allergic rhinitis

scholarly journals Effect of a Novel Photoelectrochemical Oxidation Air Purifier on Nasal and Ocular Allergy Symptoms

2018 ◽  
Vol 9 ◽  
pp. 215265671878160 ◽  
Author(s):  
Nikhil G. Rao ◽  
Ambuj Kumar ◽  
Jenny S. Wong ◽  
Ravi Shridhar ◽  
Dharendra Y. Goswami
Keyword(s):  
Nasal Symptom ◽  
Mean Difference ◽  
Air Purification ◽  
Ocular Allergy ◽  
Photoelectrochemical Oxidation ◽  
Symptom Scores ◽  
Air Purifier ◽  
Significant Change ◽  
Device Use ◽  
Continuous Use

Background Photoelectrochemical oxidation (PECO) is a new air purification technology developed to reduce circulating indoor allergens. PECO removes particles as small as 0.1 nm with the destruction of organic matter otherwise not trapped by a traditional filter and removes volatile organic compounds. Objective We hypothesized that with daily use, the device would reduce user nasal and ocular allergy total symptom scores (TSS) within 4 weeks. Methods The study was performed among 46 individuals with self-reported allergies using a portable PECO air purifier. Self-reported TSS were calculated at baseline and weekly for 4 weeks following initiation of continuous use of the system. TSS was the sum of total nasal symptom scores (TNSS) and total ocular symptom scores (TOSS) for the week. Results There was a statistically significant change in overall TSS from baseline to 4 weeks (10.1 at baseline and 4.35 postintervention) resulting in a mean difference of 5.75 (95% confidence interval [CI] 4.32–7.18; P < .0001). There was a statistically significant change in TNSS from baseline to 4 weeks (6.3 at baseline and 3.04 postintervention) resulting in a mean difference of 3.26 (95% CI 2.33–3.19; P < .0001). There was a statistically significant change in TOSS from baseline to 4 weeks (3.82 at baseline and 1.3 postintervention) resulting in a mean difference of 2.52 (95% CI 1.74–3.3; P < .0001). Conclusion With the use of PECO air purification technology, TSS, TNSS, and TOSS decreased significantly. These improvements were consistent over the 4-week course of device use.

Sublingual immunotherapy in patients with house dust mite allergic rhinitis: prospective study of clinical outcomes over a two-year period

2016 ◽  
Vol 130 (3) ◽  
pp. 272-277 ◽  
Author(s):  
J Y Soh ◽  
M Thalayasingam ◽  
S Ong ◽  
E X L Loo ◽  
L P Shek ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Allergic Rhinitis ◽  
House Dust ◽  
House Dust Mite ◽  
Sublingual Immunotherapy ◽  
Nasal Symptom ◽  
Medication Usage ◽  
Dust Mite ◽  
Symptom Scores

AbstractBackground:Sublingual immunotherapy in patients with allergic rhinitis sensitised to house dust mites is safe, but its efficacy is controversial and sublingual immunotherapy withBlomia tropicalishas not yet been studied. This study sought to evaluate the efficacy of sublingual immunotherapy with house dust mite extract in children and adults with house dust mite allergic rhinitis over a period of two years.Methods:A prospective observational study was conducted of children and adults diagnosed with house dust mite allergic rhinitis who were treated with sublingual immunotherapy from 2008 to 2012. Total Nasal Symptom Scores, Mini Rhinoconjunctivitis Quality of Life scores and medication usage scores were assessed prospectively.Results:Thirty-nine patients, comprising 24 children and 15 adults, were studied. Total Nasal Symptom Scores and Mini Rhinoconjunctivitis Quality of Life scores dropped significantly at three months into therapy, and continued to improve. Medication usage scores improved at one year into immunotherapy.Conclusion:Sublingual immunotherapy with house dust mite extracts, includingB tropicalis, is efficacious as a treatment for patients with house dust mite allergic rhinitis.

Sign in / Sign up

Export Citation Format

Share Document